- Home
- DD vs UTHR Comparison
DD vs UTHR Comparison
Compare DD & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DD | UTHR |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 20.3B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | DD | UTHR |
|---|---|---|
| Price | $40.42 | $494.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $67.58 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 5.0M | 423.0K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | N/A | ★ 26.38 |
| Revenue | ★ $12,843,000,000.00 | $3,128,400,000.00 |
| Revenue This Year | N/A | $13.64 |
| Revenue Next Year | $3.36 | $5.78 |
| P/E Ratio | ★ N/A | $18.73 |
| Revenue Growth | ★ 15.07 | 13.50 |
| 52 Week Low | $33.34 | $266.98 |
| 52 Week High | $85.00 | $496.73 |
Technical Indicators
Market Signals| Indicator | DD | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 34.15 | 66.02 |
| Support Level | $38.93 | $474.59 |
| Resistance Level | $41.83 | $489.99 |
| Average True Range (ATR) | 0.87 | 10.11 |
| MACD | 1.40 | -0.40 |
| Stochastic Oscillator | 63.47 | 85.52 |
Price Performance
Historical ComparisonAbout DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.